博瑞医药跌2.01%，成交额1.09亿元，主力资金净流出306.29万元

Core Viewpoint - 博瑞医药's stock price has shown significant volatility, with a year-to-date increase of 76.72%, but a notable decline of 28.13% over the past 20 days and 49.41% over the past 60 days [2] Company Overview - 博瑞医药, established on October 26, 2001, and listed on November 8, 2019, is located in Suzhou, Jiangsu Province, and specializes in the research and production of high-end generic drugs and original new drugs [2] - The company's revenue composition includes 89.90% from product sales, 6.77% from technology rights and services, and 3.33% from other sources [2] - As of June 30, 2025, 博瑞医药 reported a revenue of 537 million yuan, a year-on-year decrease of 18.28%, and a net profit attributable to shareholders of 17.17 million yuan, down 83.85% year-on-year [2] Stock Performance - As of October 29, 博瑞医药's stock price was 53.20 yuan per share, with a market capitalization of 22.509 billion yuan [1] - The stock experienced a decline of 2.01% on the same day, with a trading volume of 1.09 billion yuan and a turnover rate of 0.48% [1] - The net outflow of main funds was 3.0629 million yuan, with significant selling pressure observed [1] Shareholder Information - 博瑞医药 has distributed a total of 246 million yuan in dividends since its A-share listing, with 129 million yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders decreased by 10.11% to 9,568, while the average circulating shares per person increased by 11.32% to 44,185 shares [2][3] - Notable changes in institutional holdings include a reduction in shares held by Hong Kong Central Clearing Limited and the entry of new shareholder Innovation Drug [3]